Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier
Identification and Quantification of the Effects of a Surgery-induced Peripheral Inflammatory Response on Changes in Drug Efflux Transporter Function in the Brain
1 other identifier
interventional
35
1 country
1
Brief Summary
The purpose for this study is to determine if surgery (repair of descending thoracic aneurysm) causes a temporary decrease in the Blood Brain Barrier's ability to remove drugs from the brain back into the blood. The Blood Brain Barrier surrounds the brain and the spinal cord. This Blood Brain Barrier acts as a filter and allows some things to cross into the brain and allows other matter to be removed. Studies have shown the Blood Brain Barrier is affected by inflammation. Functions of the Blood Brain Barrier in animals have been studied. Human studies with multiple causes of inflammation (e.g. Alzheimer's, Epilepsy, trauma and severe infections in critically Hypothesis: Surgically-induced inflammation will temporarily reduce blood-brain barrier drug efflux transporter function in proportion to the degree of inflammation. The investigators anticipate that inflammation-mediated reductions in drug transporter function will be reflected by an increased cerebral spinal fluid (CSF) concentration of morphine (a PGP substrate) and M3G and M6G (MRP1 substrates). The corresponding in vitro studies will allow us to elucidate the mechanism(s) by which inflammation alters blood brain barrier efflux transport of morphine, M3G and M6G.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started May 2009
Longer than P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 7, 2009
CompletedFirst Posted
Study publicly available on registry
April 8, 2009
CompletedStudy Start
First participant enrolled
May 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2013
CompletedJune 23, 2016
June 1, 2016
3.8 years
April 7, 2009
June 22, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary outcome variables are the correlation between the ratio of CSF/plasma morphine , morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) levels and the plasma concentration of IL-6 over time.
CSF and Blood samples will be taken in the OR, post operatively ( every 6 hrs until POD 5 if CSF drain still in place)
Secondary Outcomes (2)
Correlation between CSF/Plasma ratios of morphine, M3G, M6G and plasma concentration of TNFα and ET-1 over time.
CSF and Blood samples will be taken in the OR, post operatively ( every 6 hrs until POD 5 if CSF drain still in place)
Correlation between CSF/plasma ratios for morphine, M3G, M6G and CSF/Plasma ratios for albumin and S-100β over time.
CSF and Blood samples will be taken in the OR, post operatively ( every 6 hrs until POD 5 if CSF drain still in place)
Study Arms (1)
morphine
OTHERAll patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
Interventions
All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
Eligibility Criteria
You may qualify if:
- Subjects who are to undergo elective surgery for thoracic aortic vascular disease requiring insertion of a lumbar CSF drain
- Informed consent will be obtained from the subject or authorized legal representative -
You may not qualify if:
- Unwilling or unable to provide informed consent
- Sensitivity or documented allergy to morphine
- Inability to place lumbar CSF drain
- Dialysis dependent -
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Nova Scotia Health Authoritylead
- Dalhousie Universitycollaborator
Study Sites (1)
Capital Health- Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H3A7, Canada
Related Publications (3)
Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1245-64. doi: 10.1517/17425255.4.10.1245.
PMID: 18798696BACKGROUNDRoberts DJ, Hall RI, Wang Y, Julien LC, Wood J, Goralski KB. S100B as a biomarker of blood-brain barrier disruption after thoracoabdominal aortic aneurysm repair: a secondary analysis from a prospective cohort study. Can J Anaesth. 2021 Dec;68(12):1756-1768. doi: 10.1007/s12630-021-02110-2. Epub 2021 Sep 27.
PMID: 34570352DERIVEDWang Y, Goralski KB, Roberts DJ, Landry K, Issa ME, Sleno L, Julien LC, Wood J, Hall RI. An observational study examining the effects of a surgically induced inflammatory response on the distribution of morphine and its metabolites into cerebrospinal fluid. Can J Anaesth. 2017 Oct;64(10):1009-1022. doi: 10.1007/s12630-017-0933-x. Epub 2017 Jul 14.
PMID: 28710563DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Richard I Hall, MD
Capital Health- Queen Elizabeth II Health Sciences Center
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD FRCPC FCCP
Study Record Dates
First Submitted
April 7, 2009
First Posted
April 8, 2009
Study Start
May 1, 2009
Primary Completion
February 1, 2013
Study Completion
February 1, 2013
Last Updated
June 23, 2016
Record last verified: 2016-06
Data Sharing
- IPD Sharing
- Will share
publication in process